Leukemia Research


Publication Venue For

  • Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors.  82:1-6. 2019
  • The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).  78:29-33. 2019
  • Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.  75:29-35. 2018
  • Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.  74:64-67. 2018
  • Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).  67:17-20. 2018
  • Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin.  44:25-31. 2016
  • Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.  42:68-74. 2016
  • Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis.  39:1342-1346. 2015
  • Early mortality in acute myeloid leukemia.  39:505-509. 2015
  • Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.  39:183-191. 2015
  • Transcript variants of RUNX1T1: new insight into t(8;21)-positive leukemia..  38:1018-1019. 2014
  • N-Cadherin and Tie2 positive CD34+CD38−CD123+ leukemic stem cell populations can develop acute myeloid leukemia more effectively in NOD/SCID mice.  38:632-637. 2014
  • Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.  38:329-333. 2014
  • Iron chelators induce autophagic cell death in multiple myeloma cells.  38:988-996. 2014
  • Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway.  37:1719-1725. 2013
  • Clinical and laboratory studies of 17 patients with acute myeloid leukemia harboring t(7;11)(p15;p15) translocation.  37:1010-1015. 2013
  • Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.  36:1152-1156. 2012
  • Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.  36:966-973. 2012
  • Roles of p15Ink4b and p16Ink4a in myeloid differentiation and RUNX1-ETO-associated acute myeloid leukemia.  32:1101-1111. 2008
  • Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.  31:261-265. 2007
  • Therapy of acute myelogenous leukemia in patients over the age of 50: A randomized southeastern cancer study group trial.  14:895-903. 1990
  • Effects of N,N-dimethylformamide and sodium butyrate on enzymes of pyrimidine metabolism in cultured human tumor cells.  11:855-861. 1987
  • Tumoricidal activity of an acute promyelocytic leukemia cell line (HL-60) is augmented by human interferon alpha.  8:801-811. 1984
  • International Standard Serial Number (issn)

  • 0145-2126
  • Electronic International Standard Serial Number (eissn)

  • 1873-5835